Market Overview

KeyBanc Upgrades Catalent On Industry Transformation

Share:
KeyBanc Upgrades Catalent On Industry Transformation

Catalent Inc (NYSE: CTLT) is a “key component” of the transformation of the health care industry from pharma to biopharma, according to KeyBanc Capital Markets.

The Catalent Analyst: Paul Knight upgraded Catalent from Sector Weight to Overweight with a $120 price target. 

The Catalent Thesis: An accelerating number of biotech therapies are being approved by the FDA, easily doubling the pace seen in 2000-2010, Knight said in an upgrade note.

Amid this trend, contract development and manufacturing organizations “have become of increasing strategic importance to biopharma as companies rationalize their supply chain and molecules become increasingly complex to develop and manufacture” the analyst said. 

Catalent's biologic capabilities previously lacked an integrated offering and scale, he said.

“The acquisition of Cook Pharmica in 2017 brought increased scale and technological capability into CTLT's network. Further with 1,109 CGT Clinical Trials ongoing and 5 approved by the FDA, CTLT gained exposure to this end market with acquisitions Paragon Bioservices, and MasTHerCell,” Knight said.   

“Management's recent organic and inorganic investments lead us to believe that its long-term outlook of 6-8% is not only achievable but conservative.” 

CTLT Price Action: Shares of Catalent were up 4% at $96.01 at last check Thursday.

Latest Ratings for CTLT

DateFirmActionFromTo
Dec 2020KeyBancUpgradesSector WeightOverweight
Nov 2020Morgan StanleyMaintainsOverweight
Sep 2020Morgan StanleyMaintainsOverweight

View More Analyst Ratings for CTLT
View the Latest Analyst Ratings

 

Related Articles (CTLT)

View Comments and Join the Discussion!

Posted-In: KeyBanc Capital Markets Paul KnightUpgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
URIVertical ResearchInitiates Coverage On310.0
PCARVertical ResearchInitiates Coverage On95.0
DEVertical ResearchInitiates Coverage On345.0
CNHIVertical ResearchInitiates Coverage On16.0
AGCOVertical ResearchInitiates Coverage On119.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com